Oral antivirals may be useful for high risk patients infected with COVID JN.1 --study

Oral antivirals may cut risk of poor outcomes in high-risk patients infected with COVID JN.1 Critics said today’s announcement is more evidence of the current administration’s willingness to undermine public trust in vaccines. CIDRAP

Oral antiviral drugs significantly lowered the risk of adverse outcomes in high-risk COVID-19 patients during the Omicron JN.1 subvariant wave in the United States, concludes a new study published in Pneumonia.

JN.1 first emerged in August 2023, was dominant by early 2024, and is still circulating widely today.

...